Why Mylan? See inside.

Learn how Mylan has been providing access to high quality medicine for more than 50 years… and counting.

February 2013

Mylan®
Seeing is believing™



At Mylan, our purpose is Access

Mylan®
Seeing is believing™




To us, our mission isn't just words.
It's a cause we've made personal.

OUR MISSION: At Mylan, we are committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership.




To achieve our mission, we built a strong foundation.

- One of the world's leading generics and specialty pharmaceutical companies
- Global workforce of more than 18,000
- 2011 revenue of more than $6B
- 1 of every 11 prescriptions in the U.S., brand name or generic, is filled with a Mylan product
- More than 1,100 separate products

- Manufacturing capacity of ~45 billion doses
- Products provided in ~150 countries and territories
- One of the world's largest active pharmaceutical ingredient (API) manufacturers
- World-class branded specialty pharmaceutical business, including EpiPen® Auto-Injector

Mylan®
Seeing is believing™

Vertically integrated manufacturing platform

Global capacity of ~45 billion doses today

North America
U.S. and Puerto Rico

Capabilities

OSD, transdermal patches, semi-solid, nebules and packaging

Capacities

	2012	2016
OSD	26B doses	28B doses
All other	870M units	1B units

EMEA
Ireland, France and Hungary

Capabilities

OSD, dry powder inhaler, injectables and packaging

Capacities

	2012	2016
OSD	2B doses	4B doses
All other	11M units	127M units

APAC
Australia, India, China and Japan

Capabilities

OSD, API and packaging

Capacities

	2012	2016
OSD	17B doses	50B doses
API	3,000	4,500

API reactor capacities in kiloliters

Providing high quality products, massive scale, and supply reliability

One of the world's largest pharmaceutical manufacturing facilities located in W.Va. – capable of producing ~20 billion doses a year

Powerful science and innovation

~1,300 research and development employees



North America

U.S.

- Oral solid dose (OSD)
- Transdermals
- Injectables
- Topicals
- CII solids
- Liquid hard gel capsules
- Nasal sprays
- Nebules

EMEA

Ireland and U.K.

- Injectables
- Dry powder respiratory

APAC

India and Japan

- OSD
- Transdermals
- Ophthalmics
- API
- Antiretrovirals (ARVs)
- Injectables
- Nasal sprays
- Nebules

Meeting unmet needs

Mylan®
Seeing is believing

Savings from generic prescription drugs

The U.S. has saved more than $1 trillion within the past decade by using generic prescription drugs…

Biogenerics



Opportunity to provide additional savings to the U.S. health care system while continuing to expand access to high quality medicine.

Access to biogenerics is becoming increasingly important

- **Annual drug trend for specialty biologic products ~17% annually**
- **Additional products in biologic pharmaceutical pipeline**
- **By 2016, 8 of 10 top selling products will be biologics**

Mylan
Seeing is believing

Mylan's Biologic Leadership in West Virginia

- Biosimilar pathways in the US and abroad have been facilitated by advances in analytical sciences, which provide the ability to rigorously characterize the physicochemical and biological properties of protein therapeutics.
- FDA as well as other global Health Authorities consider characterization to be the foundation of a biosimilarity assessment.
- In recognition of this, Mylan is expanding its Morgantown-based R&D facility to establish a center of excellence for biosimilar characterization.
- The newly built laboratory will house a suite of state of the art analytical instrumentation.
- Mylan is currently looking to hire additional qualified bioscience staff in areas such as analytical, pharmacology and toxicology.

Providing access to the world's 7 billion people

At Mylan, our people want to change the world. We'll each do our part every day to provide 7 billion people access to the high quality medicine they deserve.

Mylan®
Seeing is believing


Mylan®
Seeing
is believing

This presentation and any related Q&A may contain “forward-looking” statements, including with respect to:

- Mylan’s anticipated earnings,
- our anticipated future financial and operating performance and results and
- expectations for our products and plans for growth.

These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to:

- The impact of competition,
- changes in third-party relationships,
- changes in economic and financial condition affecting the company’s business and
- unexpected legal or regulatory challenges.

For more detailed information on the risks and uncertainties associated with the company’s business activities, please see the company’s Form 10-Q for the quarter ended June 30, 2012, and its other filings with the Securities and Exchange Commission. The company undertakes no obligation to update its forward-looking statements, whether as a result of new information, future events or otherwise.

Non-GAAP Financial Measures

Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with GAAP.

Please refer to Mylan’s earnings press release, dated July 26, 2012, for a reconciliation of certain non-GAAP financial measures included in this presentation to the most directly comparable financial measure calculated and presented in accordance with GAAP. That press release is available in the Investor Relations section of Mylan’s website. In addition, see the company’s past quarterly earnings releases for additional GAAP to non-GAAP reconciliations, available at mylan.com.

Mylan®
Seeing is believing